Imatinib Terapia (Imatinib)

Imatinib Terapia is used to treat malignancies driven by BCR‑ABL or related tyrosine‑kinase pathways.

• Chronic myeloid leukemia (CML): reduces disease progression and improves long‑term survival in patients with BCR‑ABL positive leukemia.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by targeting the BCR‑ABL fusion protein.
• Gastrointestinal stromal tumor (GIST): inhibits c‑KIT signaling to control tumor growth in patients with KIT‑mutated disease.
• Other BCR‑ABL positive neoplasms: provides targeted therapy for rare malignancies expressing the BCR‑ABL kinase.

• Imatinib binds competitively to the ATP‑binding pocket of several tyrosine kinases, including BCR‑ABL, c‑KIT and platelet‑derived growth factor receptors (PDGFR). By preventing ATP access, it blocks phosphorylation of downstream substrates, halting proliferative and survival signaling pathways in malignant cells. The drug’s affinity for these targets is higher than for most normal cellular kinases, contributing to its therapeutic window.

Imatinib therapy is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset that may improve with food.
• Edema: swelling of the hands, feet or periorbital area.
• Fatigue: generalized tiredness not relieved by rest.
• Diarrhea: loose stools that are usually self‑limiting.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or jaundice indicating liver injury.
• Myelosuppression: significant reduction in blood cell counts, increasing infection or bleeding risk.
• Cardiotoxicity: rare cases of heart failure or reduced left‑ventricular function.

Before initiating Imatinib, clinicians should evaluate several safety considerations to minimize risk.

• Baseline laboratory assessment: obtain complete blood count, liver function tests and renal function to detect pre‑existing abnormalities.
• Cardiac evaluation: perform ECG or echocardiogram in patients with known heart disease or risk factors.
• Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers that may alter Imatinib exposure.
• Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or neonatal risks; discuss contraception.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Imatinib may affect or be affected by other medicines through metabolic pathways and transporter systems.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase Imatinib plasma levels and risk of toxicity.
• Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug exposure, compromising efficacy.
• Antacids containing aluminum or magnesium: can decrease oral absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (e.g., proton pump inhibitors): may modestly lower Imatinib absorption; monitor therapeutic response.
• Warfarin: Imatinib can enhance anticoagulant effect; check INR more frequently.
• Live vaccines: should be avoided during treatment due to immunosuppression risk.